Sphingolipid-Induced Bone Regulation and Its Emerging Role in Dysfunction Due to Disease and Infection
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25053024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Anouska Seal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biionix Cluster, University of Central Florida, Orlando, FL 32827, USA. Hauptthemen laut MEDLINE: Sphingolipids, Bone Diseases. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 351 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Aeronautics and Space Administration, NASA Office of STEM Engagement.
Abstract (Originalsprache)
The human skeleton is a metabolically active system that is constantly regenerating via the tightly regulated and highly coordinated processes of bone resorption and formation. Emerging evidence reveals fascinating new insights into the role of sphingolipids, including sphingomyelin, sphingosine, ceramide, and sphingosine-1-phosphate, in bone homeostasis. Sphingolipids are a major class of highly bioactive lipids able to activate distinct protein targets including, lipases, phosphatases, and kinases, thereby conferring distinct cellular functions beyond energy metabolism. Lipids are known to contribute to the progression of chronic inflammation, and notably, an increase in bone marrow adiposity parallel to elevated bone loss is observed in most pathological bone conditions, including aging, rheumatoid arthritis, osteoarthritis, and osteomyelitis. Of the numerous classes of lipids that form, sphingolipids are considered among the most deleterious. This review highlights the important primary role of sphingolipids in bone homeostasis and how dysregulation of these bioactive metabolites appears central to many chronic bone-related diseases. Further, their contribution to the invasion, virulence, and colonization of both viral and bacterial host cell infections is also discussed. Many unmet clinical needs remain, and data to date suggest the future use of sphingolipid-targeted therapy to regulate bone dysfunction due to a variety of diseases or infection are highly promising. However, deciphering the biochemical and molecular mechanisms of this diverse and extremely complex sphingolipidome, both in terms of bone health and disease, is considered the next frontier in the field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biionix Cluster, University of Central Florida, Orlando, FL 32827, USA.
- School of Biosciences, Cardiff University, Cardiff CF10 3AT, UK.
- College of Medicine, University of Central Florida, Orlando, FL 32827, USA.
ORCID-Profile: Fei Wei, Jonathan D Schwartzman, Melanie J Coathup
Förderung
- National Aeronautics and Space Administration
- NASA Office of STEM Engagement
Zitieren
APA
Seal, A., Hughes, M., Wei, F., Pugazhendhi, A. S., Ngo, C., Ruiz, J., Schwartzman, J. D., & Coathup, M. J. (2024). Sphingolipid-Induced Bone Regulation and Its Emerging Role in Dysfunction Due to Disease and Infection. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25053024
Vancouver
Seal A, Hughes M, Wei F, Pugazhendhi AS, Ngo C, Ruiz J, et al. Sphingolipid-Induced Bone Regulation and Its Emerging Role in Dysfunction Due to Disease and Infection. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25053024
BibTeX
@article{Seal2024,
author = {Seal, Anouska and Hughes, Megan and Wei, Fei and Pugazhendhi, Abinaya S and Ngo, Christopher and Ruiz, Jonathan and Schwartzman, Jonathan D and Coathup, Melanie J},
title = {Sphingolipid-Induced Bone Regulation and Its Emerging Role in Dysfunction Due to Disease and Infection},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25053024}
}
EUVIMED